Sign in
4

Changes in Ownership

MoonLake Immunotherapeutics Filed Acc 0001213900-26-070259

Chief Financial Officer sold 17,876 shares at an average $19.67 ($351,576)

  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Bodenstedt Matthias Chief Financial Officer 2026-06-17 Sale 10b5-1 −15,082 $19.68 $296,814 1,157,349 D
Bodenstedt Matthias Chief Financial Officer 2026-06-18 Sale 10b5-1 −2,794 $19.60 $54,762 1,154,555 D
Open-market sales · 17,876 sh · avg $19.67 · $351,576
Loading xslF345X06/ownership.xml…